Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation

View original at seekingalpha.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation Earnings Call Insights: Ibotta, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • LiveLift is the most sophisticated capability and represents where the industry is heading

    80% confidence
  • Third-party redeemer growth attributed to new publisher partnerships and innovations in in-store and online awareness

    80% confidence
  • Clients can purchase sales lift studies just as they would for other forms of digital media through partnerships with Circana and ABCS Insights

    80% confidence
  • There's real emphasis on value among clients and Ibotta is well positioned in terms of the macro environment

    80% confidence
  • More offers, better quality offers, and longer duration on network drive more redemptions per redeemer

    80% confidence
  • Q4 revenue and adjusted EBITDA were 7% and 31% above the midpoint of Q3 guidance respectively

    80% confidence
  • Low single-digit sequential revenue growth expected in Q2 versus Q1, and slight year-over-year revenue growth expected in Q3

    80% confidence
  • Q1 2026 revenue expected in range of $78 million to $82 million, representing 5% year-over-year decline at midpoint

    80% confidence
  • Broad-based sequential progress in year-over-year redemption revenue trends throughout Q4, with LiveLift revenue better than projected and SNAP program contributing incremental revenue

    80% confidence
  • LiveLift allows clients to see projected incremental sales and cost per incremental dollar at various intervals during campaigns, enabling better optimization

    80% confidence
  • Companies added additional budget to same brands and added additional brands into the program

    80% confidence
  • Q1 2026 adjusted EBITDA expected in range of $6 million to $8 million, representing about 9% adjusted EBITDA margin at midpoint

    80% confidence
  • Stock-based compensation expense expected to be approximately $10 million higher than 2025

    80% confidence
  • LiveLift is a TAM expander with ability to provide ongoing, actionable metrics

    80% confidence
  • Q4 revenue and adjusted EBITDA are both above the top end of the guidance range, representing an improvement in year-over-year revenue trends compared to Q3

    80% confidence
  • Outperformance attributed to improved execution, core product strengthening, and expansion of LiveLift

    80% confidence
  • Average campaign size in LiveLift from companies piloting it is substantially larger than average campaign size in core Ibotta offering from same companies

    80% confidence
  • Third-party redeemers grew by almost 3.5 million in Q4, with about one-third from existing publishers

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com